Solid Biosciences Inc.
SLDB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $8 | $14 |
| % Growth | – | -100% | -40.6% | – |
| Cost of Goods Sold | $2 | $3 | $0 | $0 |
| Gross Profit | -$2 | -$3 | $8 | $14 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $96 | $77 | $78 | $59 |
| G&A Expenses | $33 | $28 | $29 | $27 |
| SG&A Expenses | $33 | $28 | $29 | $27 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2 | -$3 | $7 | $0 |
| Operating Expenses | $127 | $102 | $115 | $86 |
| Operating Income | -$130 | -$104 | -$106 | -$72 |
| % Margin | – | – | -1,315.2% | -530.5% |
| Other Income/Exp. Net | $5 | $8 | $20 | $0 |
| Pre-Tax Income | -$125 | -$96 | -$86 | -$72 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$125 | -$96 | -$86 | -$72 |
| % Margin | – | – | -1,062.3% | -530% |
| EPS | -3.06 | -4.83 | -10.1 | -10.14 |
| % Growth | 36.6% | 52.2% | 0.4% | – |
| EPS Diluted | -3.06 | -4.83 | -10.1 | -10.14 |
| Weighted Avg Shares Out | 41 | 20 | 9 | 7 |
| Weighted Avg Shares Out Dil | 41 | 20 | 9 | 7 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9 | $7 | $3 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $3 | $2 | $3 |
| EBITDA | -$122 | -$93 | -$97 | -$69 |
| % Margin | – | – | -1,196.8% | -508.7% |